~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! #LCSM 1/

Surgical outcomes correlation with 5 year survival with neoadj chemo IO for lung cancer in CheckMate 816 presented by the legendary Prof. @t_mitsudomi #WCLC25 overall v good outcomes, remarkably so for pts with pneumonectomy #LCSM

RT @DrJNaidoo: #WCLC25. Super proud of nurse specialist🇮🇪 @CancerCentreIre Ornagh Kestell for her incredibly thoughtful talk on how to navi….

Great to see not one, but two investigator-initiated clinical trials reported side by side at #WCLC25 ! These ain’t easy but they got them done! #LCSM.

RT @bmassutis: 76.9% surgery conversion rate and 55% pathological complete response in “considered unresectable” St III after induction Tis….

Finally at #wclc25 plenary labor of love phase 3 trial led by Dr. David Gerber, no benefit from adj crizotinib in resected ALK pos lung cancer. Somewhat surprising but important results, despite lower cost crizotinib cannot be substituted effectively for adjuvant alectinib #LCSM

Now @alexdrilon #wclc25 with ARROS-1 zidesamtinib for ROS1 lung cancer - overall an impressive drug, active in heavily pretreated disease (4 prior TKIs) & importantly avoids TRK mediated neurotox. Early 1st line data also encouraging given the good tox profile #LCSM

#wclc25 Much awaited Harmoni by Dr. Jonathan Goldman - ivonescimab - large differential follow up between Asia and rest of world & OS not stat sig. Exploratory long term f/u w similar absolute OS between China/Asia & rest of world - perhaps reassuring for future development #LCSM

Next up at #wclc25 Prof. Jie Wang, w p3 China only study of 3rd gen TKI aumolertinib plus chemo in EGFR tumors with poorer prognosis tumor suppressor gene mut, PFS improved, OS immature. May show a path to elucidate which pts may benefit from intensified therapy #LCSM

RT @DrJNaidoo: #WCLC25. @IASLC Awards Luncheon.Congrats to PhD Fellow @DavidOReilly2 on his Adi Gazdar grant🏆. Thanks to colleagues & colla….

1st up in #wclc25 plenary - @dplanchard w positive OS results from FLAURA2. Overall an important advance - pts in chemo-osi arm had long periods with just osi maintenance & there were high rates of post protocol SOC in the control - perhaps jumps ahead of Ami-Laz? #LCSM

RT @AmyNolanDublin: Representing @IrishCancerSoc at 𝗜𝗔𝗦𝗟𝗖 World Conference on Lung Cancer #wclc2025 💛🫁. Largest int’l gathering of lung can….

RT @DrJNaidoo: @FordePatrick @RCSI_Irl @CancerCentreIre @IrishCancerSoc @cancertrials_ie @IASLC ♥️ thanks Patrick, you’re the best. What a….

RT @StephenVLiu: Congratulations to the 2025 @IASLC, distinguished service award winners! Grateful for all the impact and happiness is the….

Congratulations to my colleague & friend Prof. @DrJNaidoo from @RCSI_Irl @CancerCentreIre co-leading one of the largest cancer conferences worldwide now on in Barcelona, she is proudly representing 🇮🇪 globally! @IrishCancerSoc @cancertrials_ie @IASLC.

@MattSmeltzer @NarjustFlorezMD @DoctorJSpicer Now a panel discussion on choosing a career path #wclc25

@MattSmeltzer @NarjustFlorezMD @DoctorJSpicer among the lung med oncs favorite surgeons describes his path as a clinician scientist! #wclc25

@MattSmeltzer Great (and entertaining!) talk from Dr. @NarjustFlorezMD on growing into your career! #LCSM #wclc25

Now Dr. @MattSmeltzer giving a primer on biostatistics for clinical investigators #WCLC25 #LCSM

Excellent opening career development workshop at #WCLC25 focused on developing clinical research projects in early career led by Dr. @JairBar4 now in room 3! #lcsm

RT @chulkimMD: Join us tomorrow morning at the Early Career Investigator Workshop, where I will share insights from our ongoing investigato….